Novo Nordisk halts CLARION-CKD trial, recognizes DKK 5.7B loss for ocedurenone.

Novo Nordisk has stopped its CLARION-CKD phase 3 trial investigating ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease. The trial failed to meet its primary endpoint of change in systolic blood pressure. Consequently, Novo Nordisk will recognize an impairment loss of around DKK 5.7 billion related to ocedurenone in the second quarter of 2024.

Articles

GlobeNewswire

Yahoo Finance UK

BNN Bloomberg

Market Screener

Finanz Nachrichten

www.investegate.co.uk:443

-- show less --

Further Reading

Related Stories